Amyotrophic Lateral Sclerosis News and Research

RSS

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries.

12 Aug 2014

ALS Association awards 21 new research grants to find cure for amyotrophic lateral sclerosis

The ALS Association announced today that it has awarded 21 new research grants totaling nearly $3.5 million to find treatments and a cure for amyotrophic lateral sclerosis (ALS). The grants were awarded to scientists from laboratories located in nine different states in the United States as well as from the United Kingdom, France, Canada, Switzerland, Israel and Australia.

11 Aug 2014

Researchers take major step forward in developing real ALS treatments

A series of studies begun by Harvard Stem Cell Institute scientists eight years ago has lead to a report published today that may be a major step forward in the quest to develop real treatments for amyotrophic lateral sclerosis, ALS, or Lou Gehrig's disease.

7 Aug 2014

Penn physiologist receives Javits Neuroscience Investigator Award from NIH

Erika Holzbaur, PhD, a professor of Physiology in the Perelman School of Medicine at the University of Pennsylvania, has received the Javits Neuroscience Investigator Award from the National Institutes of Health.

6 Aug 2014

Neuralstem doses final patient with NSI-566 stem cells in Phase II trial

Neuralstem, Inc. announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

4 Aug 2014

Viewpoints: Medicare's future finances; 'promising deal' on VA; Texas 'war on abortion'

Medicare got some good news Monday, when the trustees who oversee its finances announced that the fund that pays for hospital care will remain solvent until 2030, four years longer than its forecast from last year.

30 Jul 2014

New editorial calls for sports authorities to consider long-term effects of cerebral concussion

An editorial published today in The Lancet Neurology calls for sports authorities to take into consideration the long term neurological problems that repeated concussions can cause.

15 Jul 2014

Persons with reduced levels of TREM2 protein at greater risk for neurodegenerative diseases

Persons with reduced levels of the TREM2 protein could be at greater risk of developing neurodegenerative diseases such as Alzheimer's disease or frontotemporal dementia, according to an international study which included the participation of the Universitat Autònoma de Barcelona and the Sant Pau Biomedical Research Institute.

3 Jul 2014

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

ALS stands for Amyotrophic Lateral Sclerosis, better known as “Lou Gehrig’s Disease”. It is a progressive neurodegenerative disease characterized by the death of motor neurons in the brain and spinal cord.

30 Jun 2014

Increasing clearance of ALS misfolded protein from neurons improves their survival

In work supported by The ALS Association, researchers have shown that increasing the clearance of misfolded protein from neurons improves their survival. The study was published today in the journal Nature Chemical Biology.

30 Jun 2014

ALS is aggravated by over-activity of HDAC6 enzyme, shows study

Scientists at VIB and KU Leuven have demonstrated in fruit-flies that over-activity of the enzyme HDAC6 in the nerve ends exacerbates the symptoms of the neurodegenerative condition Amyotrophic Lateral Sclerosis (ALS / Lou Gehrig's Disease). Inhibition of this enzyme could offer a protective effect against ALS.

27 Jun 2014

Research finding could open new opportunities for treating Huntington's disease

Researchers believe they have learned how mutations in the gene that causes Huntington's disease kill brain cells, a finding that could open new opportunities for treating the fatal disorder. Scientists first linked the gene to the inherited disease more than 20 years ago

24 Jun 2014

Alternative disposal process in optic nerve cells has implications for neurodegenerative diseases

Biologists have long considered cells to function like self-cleaning ovens, chewing up and recycling their own worn out parts as needed.

20 Jun 2014

Neurobiologist Thomas Jessell to be honored with 2014 Gruber Neuroscience Prize

Thomas Jessell, PhD, the Claire Tow Professor of Motor Neuron Disorders in the Departments of Neuroscience and of Biochemistry and Molecular Biophysics at Columbia University, is the recipient of the 2014 Neuroscience Prize of The Gruber Foundation.

4 Jun 2014

Researchers reveal potential new drug target for dementia

Researchers at King's College London have discovered how a molecular 'scaffold' which allows key parts of cells to interact, comes apart in dementia and motor neuron disease, revealing a potential new target for drug discovery.

4 Jun 2014

New research shows how misfolded proteins are precisely selected for degradation

It's almost axiomatic that misfolded proteins compromise how cells normally function and cause debilitating human disease, but how these proteins are detected and degraded within the body is not well understood.

30 May 2014

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Leaders from academic institutions, non-profit organizations, and pharmaceutical companies will meet in Cambridge, Mass., on Monday, May 19, to discuss biomarkers in amyotrophic lateral sclerosis (ALS).

19 May 2014

Novogen partners with Genea Biocells to accelerate testing for neurodegenerative diseases

Novogen Limited, an oncology drug development company, today announced a collaboration with Australian company, Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles.

5 May 2014

Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis

Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.

28 Apr 2014

UT Southwestern researchers identify potential new treatment for depression

Researchers at UT Southwestern Medical Center are making breakthroughs that could benefit people suffering from depression.

23 Apr 2014